The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Clarithromycin Martindale Pharma 500 mg Powder for Concentrate for Solution for Infusion

500 milligram(s) Pdr/Conc/Soln for Infus

Martindale Pharmaceuticals LtdPA0361/025/001

Main Information

Trade NameClarithromycin Martindale Pharma 500 mg Powder for Concentrate for Solution for Infusion
Active SubstancesClarithromycin
Strength500 milligram(s)
Dosage FormPdr/Conc/Soln for Infus
Licence HolderMartindale Pharmaceuticals Ltd
Licence NumberPA0361/025/001

Group Information

ATC CodeJ01FA Macrolides
J01FA09 clarithromycin

Status

Authorised/WithdrawnWithdrawn
Withdrawn Date27/07/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back